Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.

de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S.

Cancers (Basel). 2018 May 5;10(5). pii: E134. doi: 10.3390/cancers10050134.

2.

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.

Law EK, Sieuwerts AM, LaPara K, Leonard B, Starrett GJ, Molan AM, Temiz NA, Vogel RI, Meijer-van Gelder ME, Sweep FC, Span PN, Foekens JA, Martens JW, Yee D, Harris RS.

Sci Adv. 2016 Oct 7;2(10):e1601737. eCollection 2016 Oct.

3.

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.

Liu J, Sieuwerts AM, Look MP, van der Vlugt-Daane M, Meijer-van Gelder ME, Foekens JA, Hollestelle A, Martens JW.

PLoS One. 2016 Aug 23;11(8):e0161731. doi: 10.1371/journal.pone.0161731. eCollection 2016.

4.

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.

Jansen MP, Martens JW, Helmijr JC, Beaufort CM, van Marion R, Krol NM, Monkhorst K, Trapman-Jansen AM, Meijer-van Gelder ME, Weerts MJ, Ramirez-Ardila DE, Dubbink HJ, Foekens JA, Sleijfer S, Berns EM.

Oncotarget. 2016 Jul 12;7(28):43412-43418. doi: 10.18632/oncotarget.9727.

5.

GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.

Liu J, Prager-van der Smissen WJ, Look MP, Sieuwerts AM, Smid M, Meijer-van Gelder ME, Foekens JA, Hollestelle A, Martens JW.

Cancer Lett. 2016 Jun 28;376(1):104-9. doi: 10.1016/j.canlet.2016.03.038. Epub 2016 Mar 24.

6.

A Method to Correlate mRNA Expression Datasets Obtained from Fresh Frozen and Formalin-Fixed, Paraffin-Embedded Tissue Samples: A Matter of Thresholds.

Mustafa DA, Sieuwerts AM, Smid M, de Weerd V, van der Weiden M, Meijer-van Gelder ME, Martens JW, Foekens JA, Kros JM.

PLoS One. 2015 Dec 30;10(12):e0144097. doi: 10.1371/journal.pone.0144097. eCollection 2015.

7.

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.

Kriege M, Jager A, Hollestelle A, Berns EM, Blom J, Meijer-van Gelder ME, Sieuwerts AM, van den Ouweland A, Collée JM, Kroep JR, Martens JW, Hooning MJ, Seynaeve C.

J Cancer Res Clin Oncol. 2015 Oct;141(10):1879-87. doi: 10.1007/s00432-015-1981-7. Epub 2015 May 10.

8.

High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.

Reijm EA, Timmermans AM, Look MP, Meijer-van Gelder ME, Stobbe CK, van Deurzen CH, Martens JW, Sleijfer S, Foekens JA, Berns PM, Jansen MP.

Ann Oncol. 2014 Nov;25(11):2185-90. doi: 10.1093/annonc/mdu391. Epub 2014 Sep 5.

PMID:
25193989
9.

Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.

Sieuwerts AM, Willis S, Burns MB, Look MP, Meijer-Van Gelder ME, Schlicker A, Heideman MR, Jacobs H, Wessels L, Leyland-Jones B, Gray KP, Foekens JA, Harris RS, Martens JW.

Horm Cancer. 2014 Dec;5(6):405-13. doi: 10.1007/s12672-014-0196-8. Epub 2014 Aug 15.

10.

Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.

Sieuwerts AM, Lyng MB, Meijer-van Gelder ME, de Weerd V, Sweep FC, Foekens JA, Span PN, Martens JW, Ditzel HJ.

Mol Oncol. 2014 Dec;8(8):1679-89. doi: 10.1016/j.molonc.2014.07.003. Epub 2014 Jul 10.

11.

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.

Kriege M, Hollestelle A, Jager A, Huijts PE, Berns EM, Sieuwerts AM, Meijer-van Gelder ME, Collée JM, Devilee P, Hooning MJ, Martens JW, Seynaeve C.

Br J Cancer. 2014 Aug 26;111(5):1004-13. doi: 10.1038/bjc.2014.306. Epub 2014 Jun 10.

12.

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.

van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van 't Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM.

Pharmacogenomics. 2011 Aug;12(8):1137-46. doi: 10.2217/pgs.11.54. Epub 2011 Aug 10.

PMID:
21830868
13.

MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer.

Rodríguez-González FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, Martens JW, Foekens JA.

Breast Cancer Res Treat. 2011 May;127(1):43-51. doi: 10.1007/s10549-010-0940-x. Epub 2010 May 19.

PMID:
20490652
14.

Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.

van Agthoven T, Sieuwerts AM, Meijer D, Meijer-van Gelder ME, van Agthoven TL, Sarwari R, Sleijfer S, Foekens JA, Dorssers LC.

Endocr Relat Cancer. 2010 Feb 18;17(1):215-30. doi: 10.1677/ERC-09-0062. Print 2010 Mar.

PMID:
19966015
15.

CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.

van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, Smid M, Brinkman A, den Dekker AT, Leroy IM, van Ijcken WF, Sleijfer S, Foekens JA, Dorssers LC.

Br J Cancer. 2009 Dec 1;101(11):1824-32. doi: 10.1038/sj.bjc.6605423. Epub 2009 Nov 10.

16.
17.

Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer.

Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, Pasa-Tolić L.

Mol Cell Proteomics. 2009 Jun;8(6):1278-94. doi: 10.1074/mcp.M800493-MCP200. Epub 2009 Mar 27.

18.

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.

van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC.

J Clin Oncol. 2009 Feb 1;27(4):542-9. doi: 10.1200/JCO.2008.17.1462. Epub 2008 Dec 15.

PMID:
19075277
19.

Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response.

Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM.

Clin Cancer Res. 2008 Sep 1;14(17):5555-64. doi: 10.1158/1078-0432.CCR-08-0555.

20.

CHEK2 1100delC and male breast cancer in the Netherlands.

Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M.

Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7. Epub 2008 Aug 31.

PMID:
18759107
21.

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Helleman J, Sleijfer S, Klijn JG, Foekens JA, Berns EM.

Breast Cancer Res Treat. 2009 Jul;116(2):263-71. doi: 10.1007/s10549-008-0125-z. Epub 2008 Jul 16.

PMID:
18629630
22.

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.

Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, Magdolen V, Portengen H, Look MP, Klijn JG, Lesche R, Schmitt M, Maier S, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2008 Oct;111(3):429-37. Epub 2007 Oct 28.

PMID:
17965955
23.

Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.

Raguz S, Randle RA, Sharpe ER, Foekens JA, Sieuwerts AM, Meijer-van Gelder ME, Melo JV, Higgins CF, Yagüe E.

Int J Cancer. 2008 Mar 1;122(5):1058-67.

24.

Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.

Kotzsch M, Sieuwerts AM, Grosser M, Meye A, Fuessel S, Meijer-van Gelder ME, Smid M, Schmitt M, Baretton G, Luther T, Magdolen V, Foekens JA.

Breast Cancer Res Treat. 2008 Sep;111(2):229-40. Epub 2007 Oct 20.

PMID:
17952591
25.

Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer.

Sieuwerts AM, Usher PA, Meijer-van Gelder ME, Timmermans M, Martens JW, Brünner N, Klijn JG, Offenberg H, Foekens JA.

Clin Chem. 2007 Jul;53(7):1280-8. Epub 2007 May 3.

26.

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.

Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van Gelder ME, van Staveren IL, Klijn JG, Foekens JA, Berns EM.

J Clin Oncol. 2007 Feb 20;25(6):662-8.

PMID:
17308270
27.

Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.

Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brünner N, Foekens JA.

Clin Cancer Res. 2006 Dec 1;12(23):7054-8. Epub 2006 Nov 17.

28.

Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.

Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3319-28.

29.

Molecular profiling of platinum resistant ovarian cancer.

Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K, Berns EM.

Int J Cancer. 2006 Apr 15;118(8):1963-71. Erratum in: Int J Cancer. 2006 Aug 1;119(3):726.

30.

How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.

Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA.

Clin Cancer Res. 2005 Oct 15;11(20):7311-21.

31.

Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.

Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Höfler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA.

Cancer Res. 2005 May 15;65(10):4101-17.

32.

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA.

Lancet. 2005 Feb 19-25;365(9460):671-9.

PMID:
15721472
33.

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, Klijn JG, Berns EM.

J Clin Oncol. 2005 Feb 1;23(4):732-40.

PMID:
15681518
34.

The prognostic value of BCAR1 in patients with primary breast cancer.

Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6194-202.

35.

Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.

Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.

Cancer Res. 2004 Jul 1;64(13):4563-8.

36.

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.

Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brünner N, Foekens JA.

Clin Cancer Res. 2004 Apr 1;10(7):2289-98.

37.

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA.

Clin Cancer Res. 2003 Apr;9(4):1253-8.

39.

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.

Cancer Res. 2002 Aug 15;62(16):4617-22.

40.

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA.

J Natl Cancer Inst. 2002 Jan 16;94(2):116-28.

PMID:
11792750
41.

Clinical relevance of biologic factors in male breast cancer.

Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA.

Breast Cancer Res Treat. 2001 Aug;68(3):249-60.

PMID:
11727961
42.

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG.

Cancer Res. 2001 Jul 15;61(14):5407-14.

43.

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.

Cancer Res. 2000 Apr 15;60(8):2155-62.

44.

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.

Cancer Res. 2000 Feb 1;60(3):636-43.

45.

Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment.

van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-van Gelder ME, Klijn JG, Dorssers LC, Foekens JA.

J Natl Cancer Inst. 2000 Jan 19;92(2):120-7.

PMID:
10639513
46.

Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.

Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JG, Foekens JA.

J Clin Oncol. 1999 May;17(5):1449-57.

PMID:
10334530
47.

Genetic alterations in ovarian borderline tumours and ovarian carcinomas.

Schuyer M, Henzen-Logmans SC, van der Burg ME, Fieret JH, Derksen C, Look MP, Meijer-van Gelder ME, Klijn JG, Foekens JA, Berns EM.

Eur J Obstet Gynecol Reprod Biol. 1999 Feb;82(2):147-50. No abstract available.

PMID:
10206406
48.

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.

Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn JG.

Br J Cancer. 1999 Feb;79(5-6):888-94.

49.

Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.

Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG.

Br J Cancer. 1999 Jan;79(2):300-7.

50.

Prognostic significance of cathepsins B and L in primary human breast cancer.

Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.

J Clin Oncol. 1998 Mar;16(3):1013-21.

PMID:
9508185

Supplemental Content

Loading ...
Support Center